Milestone Pharmaceuticals to Present Etripamil Data at Key 2024 Events

Milestone Pharmaceuticals Inc. has announced a series of upcoming data presentations on their lead investigational product, etripamil, at various key medical conferences. These presentations will highlight the latest research and clinical trial results related to etripamil, a novel nasal spray designed for self-administration by patients with certain cardiovascular conditions.

The first of these presentations will take place at ISPOR 2024, held from May 5-8 in Atlanta, GA. John Jackimiec, RPh., MBA, will present a poster titled "Analysis of Healthcare Resource Utilization in the NODE-303 Clinical Trial to Terminate Supraventricular Tachycardia (SVT) Episodes." This session is scheduled for May 6 at 3:30 pm EDT. The NODE-303 trial investigates the efficacy and resource utilization of etripamil in treating SVT episodes, a condition characterized by rapid heart rate originating above the heart's ventricles.

Following ISPOR 2024, Milestone Pharmaceuticals will participate in the 2024 Stanford BioDesign Arrhythmia Technologies Retreat in Boston, MA, on May 15. David Bharucha, MD, PhD, FACC, will present data on the use of etripamil nasal spray for acute rate control in patients with Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR). This presentation will occur at 10 am EDT.

Finally, at the Heart Rhythm 2024 annual meeting, also in Boston, MA, from May 16-19, Milestone Pharmaceuticals will provide additional insights. James Ip, MD, FACC, FHRS, will present a poster titled "Self-Administered Etripamil Nasal Spray Rapidly Terminated Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT): Analysis of Open-Label Treatment in the RAPID Study." This presentation is set for May 18 at 3:30 pm EDT.

Etripamil is positioned as a groundbreaking calcium channel blocker nasal spray, intended for patient self-administration without the need for immediate medical supervision. It aims to offer a new approach to managing symptomatic episodic attacks associated with both PSVT and AFib-RVR, providing patients with greater control over their treatment and potentially reducing the need for emergency medical interventions.

Milestone Pharmaceuticals Inc., headquartered in Montreal and Charlotte, N.C., is focused on the development and commercialization of innovative treatments for cardiovascular conditions. The company's lead product, etripamil, is part of their broader mission to address unmet patient needs and enhance the patient experience by empowering individuals to manage their heart conditions more independently.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!